This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
CryoLife, Inc. (CRY)
Lazard Capital Markets 8th Annual Healthcare Conference
November 15, 2011, 15:00 p.m. ET
Steven Anderson - Chairman, President and CEO
Ashley Lee - EVP, COO and CFO
Patrick Donnelly - Lazard Capital Markets
PresentationPatrick Donnelly - Lazard Capital Markets
Let’s get started here. And thanks for coming. I’m Patrick Donnelly, I work on a Med Tech team here at Lazard. I’m happy to have Steven Anderson and Ashley Lee with us from CryoLife, will present for about 15 minutes and have some time for Q&A as well. So, pass it over to you.
Thank you, Patrick. I’m Steve Anderson, and I’m the Founder and CEO of CryoLife. And with me today is Ashley Lee, the company’s Executive VP and CFO.
Our first line today outlines our forward-looking statements and is available in the copy of the presentation that’s posted on our Investor Relations website and I encourage you to review the forward-looking statements and other risk factors as detailed in our Form 10-K, which was filed on December 31, 2010.
CryoLife is a medical technology company, focused on products that address complex cardiac and vascular reconstruction. We have a diversified business composed of mature cash generating products and tissue preservation services and surgical sealants which are complimented by a number of earlier staged products that provide us with significant and high growth market opportunities. We have a strong sales organization with well established relationships with cardiac and vascular surgeons throughout the world.
The company’s physician relationships are further strengthened by our physician and surgical training programs. We are leveraging this unique position to expand utilization of our emerging products. And finally we believe we have a tremendous opportunity to further leverage our existing core business, our sales force and infrastructure to drive growth of additional new products in the cardiac and vascular surgery space. We are using our strong balance sheet to actively search for potential acquisitions and invest in research and development to advance our internal pipeline of products and accelerate our growth.